New York, July, 2022: Axiom Market Research & Consulting™ added a report on global syndromic multiplex diagnostic market which includes study on infectious disease, type of syndrome, end use across various countries of key regions across the globe. The global syndromic multiplex diagnostic market was projected to grow at a CAGR of 7.54% for the forecast period 2022 to 2028. The global market is estimated and forecasted in terms of revenue (USD Million) the syndromic multiplex diagnostic market.
Rising advancement in the diagnostic technologies coupled with the rise in demand for the accurate diagnostic results have created demand for multiplex diagnostic market. Syndromic multiplex diagnostic test is affordable is providing growth of this market in developing regions where disposable income is rising. Syndromic multiplex is used for various infectious diseases including, Human Immunodeficiency Virus (HIV), Hepatitis B (HBV), Hepatitis C (HCV), Human Papillomavirus (HPV), Influenza, Chlamydia/Gonorrhea (CTGC), Tuberculosis, Methicillin-Resistant Staphylococcus Aureus, Vancomycin-Resistant Enterococcus (VRE). Rise in the prevalence of viral and bacterial infections provide lucrative market growth opportunity.
The report analyses the global Syndromic multiplex diagnostic industry based on infectious disease, type of syndrome, end-user, and geography. The Infectious disease studied in the global syndromic multiplex diagnostic market are, Human Immunodeficiency Virus (HIV), Hepatitis B (HBV), Hepatitis C (HCV), Human Papillomavirus (HPV), Influenza, Chlamydia/Gonorrhea (CTGC), Tuberculosis, Methicillin-Resistant Staphylococcus Aureus, Vancomycin-Resistant Enterococcus (VRE). The type of syndrome studied in the global syndromic multiplex diagnostic market are, Bloodstream, Respiratory, Gastrointestinal, Central Nervous System, and others. The end-user studied in the global syndromic multiplex diagnostic market are, Hospitals, Diagnostics Laboratories, Research Institutes and others. The global Syndromic multiplex diagnostic market is studied across various key countries of regions such as, North America, Europe, Asia Pacific and Rest of the World.
HIV diagnostic is remarkable progress in identifying, staging, imitating and monitoring infected individual on life saving antiretroviral therapy. Accurate diagnosis of HIV infection is key and represent the entry point of infected patients into the treatment. Early HIV detection and treatment is important because it reduce patient mortality and prevent future HIV transmissions.
Rising higher demand due to the rapid spread of infections along with the launch of new with USFDA approval that contribute major growth in the global syndromic multiplex diagnostic market. Respiratory tract infection is the most frequent cause of acute illness in developed countries. The majority of respiratory infections are caused by viruses, the most common viruses are rhinovirus, coronaviruses, influenza virus and other.
Owing to the availability of all resources at a single facility. The reduction of the overall stay of patients for treatment in hospitals with the reduced procedural time along with minimal and errors in the treatment is boosting the syndromic multiplex diagnostic market growth.
Rising adoption of advanced technologies and the availability of improved healthcare infrastructure and also rising in research and development laboratories resultant. The syndromic multiplex diagnostic demand is growing for treatments with widespread infections, rise in government supports to spread the healthcare awareness among people about various infections in the region.
The key competitor of the market includes Qiagen NV (Netherlands), Luminex Corp (US), Applied biocode corporation (US), Akonni biosystems inc. (US), Thermo fisher scientific inc. (US), Abbott Laboratories (US), Becton, Dickinson and Company (US), Hologic, Inc. (US), GenMark Diagnostics (Switzerland), Bio-Rad Laboratories (US), Infexn Laboratories Pvt. Ltd. (India), Cepheid (US), Quidel Corporation (US), Bosch Healthcare Solution (US), BioFire Diagnostics Company (US), among others.
Browse for More Details: https://www.axiommrc.com/product/11332-syndromic-multiplex-diagnostic-market-report
3 Germay Dr.Ste 4 - 4666
Wilmington DE 19804
U.S.:- + 1 (845) 875-9786
U.K.:- + 44 (0) 20 3286 9707